Well Referenced

Tag: Viscum album

Interaction of Standardized Mistletoe (Viscum Album) Extracts With Chemotherapeutic Drugs Regarding Cytostatic and Cytotoxic Effects in Vitro

This 2014 in vitro study (BMC Complementary and Alternative Medicine, PMID: 24397864) investigated the interaction between standardized mistletoe extracts (Viscum album, VAE-M and VAE-Qu) and common chemotherapeutic drugs (including doxorubicin, cisplatin, gemcitabine, docetaxel, and mitoxantrone) across multiple human cancer cell lines (breast, pancreatic, prostate, and lung). The results showed that

Read More »
June 26, 2025 No Comments

Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer

This observational cohort study evaluated the clinical safety of combining immune checkpoint inhibitors (ICIs) with Viscum album L. (mistletoe) extract in patients with advanced or metastatic cancer. Sixteen patients were included, with nine receiving both ICI and mistletoe therapy. The study found no statistically significant increase in adverse events (67%

Read More »
June 26, 2025 No Comments

Mistletoe Plant Extract in Patients With Nonmuscle Invasive Bladder Cancer: Results of a Phase Ib/IIa Single Group Dose Escalation Study

This 2015 Phase Ib/IIa single-group dose escalation study (Journal of Urology, PMID: 25910967) investigated the safety, tolerability, and preliminary efficacy of intravesical mistletoe (Viscum album) extract in 36 patients with nonmuscle invasive bladder cancer (NMIBC). Following tumor resection, patients received weekly intravesical instillations of mistletoe extract for six weeks. At

Read More »
June 26, 2025 No Comments

Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts

This systematic review analyzed 16 randomized controlled trials (RCTs), 9 non-randomized controlled trials (N-RCTs), and 12 single-arm cohort studies to evaluate the effects of anthroposophic mistletoe extract (Viscum album) in cancer therapy. Of the 17 trials assessing survival, 8 (including 5 of 10 RCTs) reported statistically significant benefits; however, no

Read More »
June 26, 2025 No Comments

Mistletoe Therapy in Oncology

This 2008 Cochrane systematic review (Cochrane Database Syst Rev, PMID: 18425885) analyzed 21 randomized controlled trials involving 3,484 cancer patients to assess the efficacy, safety, and tolerability of mistletoe (Viscum album) therapy in oncology. While six out of thirteen trials suggested potential survival benefits and fourteen out of sixteen indicated

Read More »
June 26, 2025 No Comments

NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients With Advanced Solid Tumors

This 2013 Phase I trial (Evidence-Based Complementary and Alternative Medicine, PMID: 24285980) evaluated the safety, tolerability, and immunological effects of combining mistletoe extract (Viscum album) with gemcitabine chemotherapy in 44 patients with advanced solid tumors. The combination was well tolerated up to a maximum tolerated dose of gemcitabine 1380 mg/m²

Read More »
June 26, 2025 No Comments

Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients

This observational study assessed the cost-effectiveness of adding Viscum album L. (mistletoe extract) to standard chemotherapy in patients with stage IV non-small cell lung cancer (NSCLC). Among 118 patients (mean age 63.8, 55.1% male), those receiving Viscum album plus chemotherapy had a longer adjusted mean overall survival (19.1 months) compared

Read More »
June 26, 2025 No Comments

Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On Viscum album L: A Multicenter Real-World Study

This 2020 multicenter observational study (Integrative Cancer Therapies, PMID: 32856476) evaluated the impact of adding Viscum album L. (mistletoe extract) to standard treatment in 275 patients with nonmetastasized non-small cell lung cancer (NSCLC) stages I–IIIA. Although no significant difference in overall survival (OS) was observed in the full cohort, subgroup

Read More »
June 26, 2025 No Comments

Cytotoxic Effects of the Viscum Album L. Extract on Ehrlich Tumour Cells in Vivo

This in vivo animal study investigated the cytotoxic effects of non-polar constituents from Viscum album L. (European mistletoe) on Ehrlich ascites carcinoma (EAC) cells in mice. Extracted using supercritical CO₂ and analyzed by GC/MS, the mistletoe contained novel terpenes that, when administered before and after tumor cell inoculation, significantly reduced

Read More »
June 26, 2025 No Comments

Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherap

This 2018 multicenter observational study (PLoS ONE, PMID: 30148853) assessed the impact of adding Viscum album L. (mistletoe extract) to standard chemotherapy in 158 patients with stage IV non-small cell lung cancer (NSCLC). Patients who received mistletoe alongside chemotherapy had significantly improved median overall survival (17.0 vs. 8.0 months, p=0.007)

Read More »
June 26, 2025 No Comments